uniQure NV
QUREHealthcare|Biotechnology|Netherlands
$42.63
-1.85 (-4.16%)
Tangible Book
$0.87
Upcoming Data Readouts (5)
Sep 2026
Est. completion
P1P2Amyotrophic Lateral Sclerosis
Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)
NCT06100276n=20
Nov 2026
Est. completion
P1P2Mesial Temporal Lobe Epilepsy
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy
NCT06063850n=12
Dec 2027
Est. completion
P1P2Fabry Disease
Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease
NCT06270316n=12
Mar 2029
Est. completion
P1P2Huntington Disease
Safety and Efficacy of AMT-130 in European Adults With Early Manifest Huntington's Disease
NCT05243017n=14
Jun 2029
Est. completion
P1P2Huntington's Disease
Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease
NCT04120493n=43